Company Description
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries.
It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform.
The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, is composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and phase I trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform.
It also offers cell manufacturing services; cell-based coffee; and develops and commercializes cultivated meat products.
The company operates in the field of regenerative medicine, food-tech, CDMO, and agtech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors.
The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022.
Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Contact Details
Address: Building No. 5, MATAM Advanced Technology Park Haifa, 3508409 Israel | |
| Phone | 972 74 710 8600 |
| Website | pluri-biotech.com |
Stock Details
| Ticker Symbol | PLUR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001158780 |
| CUSIP Number | 72942G104 |
| ISIN Number | US72942G2030 |
| Employer ID | 98-0351734 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Yaacov Yanay | President, Chief Executive Officer and Director |
| Liat Zalts | Chief Financial Officer and Treasurer |
| Lior Raviv | Chief Technology Officer |
| Dr. Arthur Machlenkin Ph.D. | Chief Scientific Officer |
| Efrat Livne-Hadass | Chief Wellbeing Officer |
| Orly Amiran | Chief Quality Officer |
| Efrat Kaduri | Chief Business Development Officer of Pharma |
| Nimrod Bar Zvi | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 3, 2025 | 8-K | Current Report |
| Jun 9, 2025 | SCHEDULE 13D/A | Filing |
| May 27, 2025 | ARS | Filing |
| May 27, 2025 | DEF 14A | Other definitive proxy statements |
| May 27, 2025 | 8-K | Current Report |
| May 20, 2025 | SCHEDULE 13D/A | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | SCHEDULE 13D/A | Filing |
| May 8, 2025 | 8-K | Current Report |
| Apr 29, 2025 | 8-K | Current Report |